Dementia and Geriatric Cognitive Disorders
Original Research Article
A Comparative Study of the Different N-Acetylaspartate Measures of the Medial Temporal Lobe in Alzheimer’s DiseaseJessen F.a · Traeber F.b · Freymann N.a · Maier W.a · Schild H.-H.b · Heun R.a · Block W.bDepartments of aPsychiatry and bRadiology, University of Bonn, Bonn, Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: February 23, 2005
Published online: August 19, 2005
Issue release date: August 2005
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Abstract
Objective: To investigate group differences and correlations and to determine the sensitivity and specificity of different measures of the neuronal marker N-acetylaspartate (NAA) in the medial temporal lobe of Alzheimer’s Disease (AD) patients. Methods: The metabolic ratio NAA/creatine (Cr), the absolute concentration of NAA referenced against brain tissue (BT) water and NAA multiplied with the amount of BT in the proton magnetic resonance spectroscopy (1H-MRS) voxel were assessed in patients and healthy controls with a single-voxel 1H-MRS protocol. Results: All measures were significantly lower in AD patients compared with controls. NAA/Cr and NAA correlated weakly, and there was no correlation of NAA with the amount of BT in the voxel. The highest specificity (87%) at a sensitivity of 80% was observed for NAA multiplied with the amount of BT in the voxel. There was no correlation of the MMSE with any of the NAA parameters. Conclusions: NAA/Cr does not reflect NAA concentration very well. NAA is not correlated with brain atrophy. The BT volume in the 1H-MRS voxel in combination with the concentration of NAA discriminates AD from healthy controls sufficiently.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Valenzuela MJ, Sachdev P: Magnetic resonance spectroscopy in AD. Neurology 2001;56:592–598.
- Cheng LL, Newell K, Mallory AE, Hyman BT, Gonzalez RG: Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 2002;20:527–533.
- Block W, Traber F, Kuhl CK, Fric M, Keller E, Lamerichs R, Rink H, Moller HJ, Schild HH: 1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer’s disease. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995;163:230–237.
- Block W, Jessen F, Traber F, Flacke S, Manka C, Lamerichs R, Keller E, Heun R, Schild HH: Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 2002;59:828–834.
- Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD: Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease. Brain 2002;125:2332–2341.
- Engelhardt E, Moreira DM, Laks J, Marinho VM, Rozenthal M, Oliveira AC: Alzheimer’s disease and magnetic resonance spectroscopy of the hippocampus. Arq Neuropsiquiatr 2001;59:865–870.
- Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000;55:684–688.
- Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, Schild HH, Heun R: Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930–932.
- Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW: Changes of hippocampal N-acetyl aspartate and volume in Alzheimer’s disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997;49:1513–1521.
- Schuff N, Capizzano AA, Du AT, Amend DL, O’Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW: Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002;58:928–935.
- Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO: In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999;56:185–192.
- Bottomley PA: Spatial localization in NMR spectroscopy. Ann NY Acad Sci 1987;508:333–348.
- Shen JF, Saunders JK: Double inversion recovery improves water suppression in vivo. Magn Reson Med 1993;29:540–542.
- Gredal O, Rosenbaum S, Topp S, Karlsborg MS, Werdelin L: Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997;48:878–881.
-
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group: Consensus report of the Working Group on: ‘Molecular and biochemical markers of Alzheimer’s Disease’. Neurobiol Aging 1998;19:106–116.
- Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 2003;160:2003–2011.
- Kantarci K, Xu Y, Shiung MM, O’Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR Jr: Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord 2002;14:198–207.
- Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD: Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65–72.
- Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O’Neill J, Wolkowitz OM, Jagust WJ, Chui HC, Miller BL, Yaffe K, Weiner MW: Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005;64:282–289.
- Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O’Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr: 1H MR spectroscopy in common dementias. Neurology 2004;63:1393–1398.
- Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y: Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004;1003:26–35.
- Schuff N, Capizzano AA, Du AT, Amend DL, O’Neill J, Norman D, Jagust WJ, Chui HC, Kramer JH, Reed BR, Miller BL, Yaffe K, Weiner MW: Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology 2003;61:358–364.
Article / Publication Details
Received: February 23, 2005
Published online: August 19, 2005
Issue release date: August 2005
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
